Vanda Pharmaceuticals | VNDA - Loan Capital


Vanda Pharmaceuticals reported $3.15M in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 24.75M 11.64M Jun/2026
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 543.51M 1.3M Jun/2026
J&J USD 37.34B 183M Jun/2026
Lexicon Pharmaceuticals USD 49.68M 276K Mar/2026
Ligand Pharmaceuticals USD 446.9M 704K Mar/2026
Merck USD 51.08B 4.41B Jun/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 597M 6M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 14.65B 806M Jun/2026
Takeda JPY 4.42T 50.32B Jun/2026
Teva Pharmaceutical Industries USD 12.09B 1.92B Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Veracyte USD 0 0 Mar/2025